MapLight Therapeutics (MPLT) Cash from Operations (2024 - 2025)

MapLight Therapeutics' (MPLT) quarterly Cash from Operations came in at 46829000.0 in Q4 2025, down 117.93% year-on-year from 261163133.14 in Q4 2024, and down 117.93% quarter-over-quarter from 21488000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Cash from Operations (2024 - 2025) Analysis & Trends

MapLight Therapeutics has disclosed Cash from Operations across 2 years of filings, most recently posting 46829000.0 for Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Ops. (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -1.67 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn -12.20 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -2.49 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.43 Bn
9 Abivax 91.96 Bn 91.96 Bn - -
10 MapLight Therapeutics 248.88 Mn 248.88 Mn - -46.83 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -46.83 Mn
Dec 31, 2025 -46.83 Mn
Dec 31, 2024 -21.49 Mn
Dec 31, 2024 -21.49 Mn